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Background. Adherence is critical for efficacy of tenofovir disoproxil fumarate/emtricitabine (FTC) as preexposure prophylaxis 
(PrEP).
Methods. Between February 2013 and February 2016, 398 men who have sex with men and transgender women were ran-
domized 1:1 to receive individualized texting for adherence building (iTAB) or standard care (SoC) for 48 weeks. The primary 
endpoint was dried blood spot (DBS) tenofovir diphosphate (TFV-DP) concentrations at both week 12 and the last on-drug visit of 
>719 fmol/punch (ie, adequate adherence). Secondary outcomes included DBS TFV-DP concentrations of >1246 fmol/punch (ie, 
near-perfect adherence) and plasma FTC >350 ng/mL (consistent with dosing within the past 24 hours).
Results. Concentrations >719 fmol/punch of TFV-DP were found in 88.6% of participants at week 12 and 82.5% at week 48. 
For the primary endpoint, the study arms did not differ (72.0% in iTAB and 69.2% in SoC; P > .05). For the secondary composite 
endpoint of >1246 fmol/punch the iTAB arm was superior to SoC (33.5% vs 24.8%; P = .06), reaching statistical significance when 
adjusting for age (odds ratio, 1.56 [95% confidence interval, 1.00–2.42]; P < .05). At week 48, iTAB was superior to SoC for near-per-
fect adherence (51.0% vs 37.4%; P = .02). At week 12, iTAB was superior to SoC for dosing in past 24 hours by plasma FTC (47.5% 
vs 33.3%; P = .007), but not at weeks 24, 36, and 48 (all P > .05).
Conclusions. Automated text messaging is a low-burden tool that improves durability of near-perfect PrEP adherence.
Clinical Trials Registration. NCT01761643.
Keywords. MSM; HIV; text messaging; randomized controlled trial; preexposure prophylaxis. 
The efficacy of tenofovir disoproxil fumarate (TDF) combined 
with emtricitabine (FTC) for preexposure prophylaxis (PrEP) 
is documented in several randomized controlled trials [1–5]. 
In the absence of PrEP, human immunodeficiency virus (HIV) 
incidence of at-risk men who have sex with men (MSM) has 
been found to be high in prevention studies such as Project 
EXPLORE (2.1 per 100 person-years) [6] and in the con-
trol groups for PrEP studies such as Intervention Préventive 
de l’Exposition aux Risques avec et pour les Gays (iPERGAY) 
(6.60 per 100 person-years) [7] and Pre-exposure Option for 
reducing HIV in the UK: immediate or Deferred (PROUD) 
(9.0 per 100 person-years) [8]. The pre-exposure prophylaxis 
initiative (iPrEx) study showed that TDF/FTC reduced the risk 
of HIV infection by 42% compared to placebo overall and by 
68% among those who had 90% self-reported adherence [1]. 
The risk of HIV infection was reduced by >90% among study 
participants with high adherence as measured by tenofovir 
drug concentrations [9]. Real-world studies support high PrEP 
effectiveness for individuals who remain adherent [10, 11]. On 
the other hand, several large studies have also shown adverse 
consequences of PrEP poor adherence [2, 12–14]. Therefore as 
PrEP use expands, novel approaches to maximize adherence are 
needed.
Use of short message service (SMS), widely known as text 
messaging, to improve adherence to antiretroviral medication 
in persons living with HIV infection has been studied in multi-
ple, mostly small, short-duration clinical studies. Several stud-
ies and a meta-analysis suggest that text messaging improves 
self-reported antiretroviral adherence among those living with 
HIV [13, 15, 16]. We developed and implemented personal-
ized text messaging systems for adherence promotion among 
persons living with HIV (individualized texting for adherence 
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building; iTAB) and shown that iTAB can be tailored to sub-
populations, leading to better antiretroviral therapy dose timing 
[17–19]. To date, no large study has evaluated text messaging to 
promote adherence to PrEP, nor has any study used the objec-
tive endpoints of drug concentrations.
Tenofovir diphosphate (TFV-DP) measured in dried blood 
spots (DBSs) provides an indicator of durable adherence due 
to a 17-day half-life. In iPrEx [1], MSM with TFV-DP intra-
cellular concentrations commensurate with 4 or more TDF/
FTC doses per week had 96% protection against HIV infection 
(≥719 fmol/punch, or the lower quartile value for DBS concen-
trations in pharmacokinetic [PK] studies) [9]. Similarly, con-
sistent daily dosing (perfect adherence) can also be determined 
as TFV-DP concentrations ≥1246 fmol/punch [20]. In contrast, 
the short half-life of emtricitabine can provide an indication of 
recent dosing. A PK study of HIV-uninfected individuals who 
stopped TDF/FTC after achieving steady state showed FTC 
plasma trough concentrations of ≥350 ng/mL at 24 hours after 
the last dose [21], providing an indicator of dosing in the last 24 
hours. This randomized controlled trial was designed to deter-
mine the effectiveness of a iTAB to support PrEP adherence in 
MSM and transgender women over 48 weeks using both intra-
cellular TFV-DP and plasma FTC drug concentrations.
METHODS
Study Setting
The California Collaborative Treatment Group enrolled subjects 
from February 2013 to February 2015 at 4 Southern California 
medical centers (University of California, San Diego; University 
of Southern California; Harbor–University of California Los 
Angeles; and Long Beach Health Department). Subjects were 
followed for a minimum of 48 weeks ending in February 2016. 
All participants provided written informed consent to partici-
pate in the institutional review board–approved study. Sample 
size of 200 subjects per group was based on a 2-sided α of .05, 
with 94% power to detect a difference of 15% between study 
arms, assuming the adherence rate for the standard of care 
(SoC) arm is 68%.
Eligibility Criteria
Eligible participants were English- or Spanish-speaking HIV-
uninfected MSM and transgender women (aged  >18  years); 
HIV was confirmed by a negative fourth-generation antigen-an-
tibody assay or a third-generation antibody assay plus HIV 
nucleic acid amplification test (NAAT). Participants had a per-
sistent elevated risk of HIV infection determined as (1) ≥1 HIV-
infected partner for ≥4 weeks; (2) condomless anal intercourse 
with ≥3 HIV-positive or unknown status male partners in prior 
3  months; or (3) condomless anal sex with ≥1 male partner 
plus a sexually transmitted infection (STI) in prior 3 months. 
Participants were required to have acceptable laboratory values 
in the past 30  days, most importantly a calculated creatinine 
clearance ≥60 mL/minute by the Cockcroft-Gault formula [22]. 
Exclusion criteria included active hepatitis B; proteinuria 2+ or 
higher; and signs or symptoms of acute HIV infection.
Study and Intervention Design
Participants were randomized 1:1 to individualized texting for 
adherence building (iTAB), a personalized, 2-way, fully auto-
mated text-messaging intervention vs SoC. Randomization was 
stratified by study site and assigned at baseline through the elec-
tronic data capture system. Participants in both the SoC and 
iTAB arms received brief HIV prevention and adherence coun-
seling with provision of study drug by study staff consistent with 
Centers for Disease Control and Prevention (CDC) guidelines 
[23]; only participants in the iTAB arm received text messages.
The iTAB intervention was developed in the context of behav-
ioral theory. Significant formative work went into developing iTAB 
for PrEP including focus groups and pilot testing to generate, 
hone, and revise the iTAB text messaging content. Importantly, 
based on feedback from participants, an emphasis was placed on 
getting participants to engage with the text messaging system (see 
Supplementary Materials for additional information). On a daily 
basis, participants received a mix of health promotion and “fac-
toid” messages at a personally selected time consistent with when 
they planned to take PrEP. Participants worked with study staff to 
choose messages consistent with their preferences from 440 differ-
ent messages. Participants could also create their own messages. At 
the end of each text message, participants were asked to respond 
with a single letter indicating whether they did or did not take PrEP. 
Results of iTAB responses were not discussed with participants at 
study visits; however, if participants reported any difficulties with 
the system, staff would provide assistance.
Study Procedures and Measures
Study visits occurred at baseline and weeks 4, 12, 24, 36, and 
48. If subjects missed 2 consecutive visits prior to week 48 they 
were discontinued from the study. Subjects were allowed to 
continue past week 48 on study drug through week 96 or until 
the last subject completed his or her week 48 visit. The pri-
mary endpoint was a priori defined at 48 weeks. At each visit, 
participants completed a confidential in-person interview and 
computer-assisted self-interviewing questionnaires. STI screen-
ing assessments at baseline and every 3–6  months included 
syphilis (serum rapid plasma reagin and, if positive, confirma-
tory treponemal test), as well as NAAT of urine and swabs of 
pharynx and rectum for chlamydia and gonorrhea (Hologic 
Aptima).
Plasma FTC was assessed at weeks 12, 24, 36, and 48 by the 
UCSD Pediatrics Pharmacology Laboratory, using liquid chro-
matography-mass spectrometry in accordance with a previously 
published method [24]. DBS concentrations for intracellular 
TFV-DP and intracellular emtricitabine triphosphate (FTC-TP) 
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were performed at week 12 (if completed) and the last study visit 
following week 12 (week 24, 36, or 48) where the participant was 
on drug and completed the visit. Both TFV-DP and FTC-TP 
were measured using a liquid chromatography–tandem mass 
spectrometry assay previously validated for the determination 
of TFV and FTC in human plasma [20]. Additional measures 
that were assessed at each visit included sexual behaviors, sexual 
compulsivity (Sexual Compulsivity Scale), depressive symptoms 
(Patient Health Questionnaire-9 [PHQ-9]), alcohol and sub-
stance use structured clinical interview for diagnostic and statis-
tical manual of mental disorders (SCID) substance use screening 
questionnaire, Drug Abuse Screening Test [DAST-10], and 
Alcohol Use Disorders Identification Test [AUDIT]), and HIV 
literacy (HIV Knowledge Questionnaire–18) [9, 25–30].
Statistical Analysis
Baseline characteristics were summarized and compared 
between study arms using Fisher exact test for categorical var-
iables and Wilcoxon rank-sum test for continuous variables. 
Primary analyses were performed on a modified intent-to-treat 
population, defined as randomized participants who completed 
the baseline visit (n = 398). The original primary outcome was 
based on self-reported adherence and FTC concentrations but 
prior to completion of the study, database lock, or any analysis of 
adherence, the primary endpoint was changed to DBS TFV-DP 
concentrations with funding provided by Gilead Sciences. The 
primary outcome was a composite outcome for being “adherent” 
defined by DBS TFV-DP concentrations that have been asso-
ciated with taking ≥4 doses of TDF in past week (≥719  fmol/
punch) 20 at week 12 visit and, if continued on PrEP past week 
12, the last study visit through week 48 (eg, week 24, 36, or 48). 
Subjects missing or discontinuing prior to the week 12 visit 
were considered nonadherent. If week 12 was the last study visit 
on-drug, then adherence was based only on that one week 12 
value. Secondary analyses for drug concentrations included 
the composite outcome for DBS TFV-DP concentration asso-
ciated with taking 7 doses of TDF in past week (≥1246  fmol/
punch; ie, “near-perfect adherence” [20]), as well as looking at 
TFV-DP concentrations at week 12 and 48 separately for those 
who completed those visits. Plasma FTC adherence was defined 
as a binary endpoint of >350  ng/mL at weeks 12, 24, 36, and 
48. The different adherence outcomes were compared between 
the study arms using Fisher exact test and multivariable logistic 
regression models adjusting for baseline factors that were associ-
ated with the outcome. Early study discontinuation and adverse 
events were compared between study groups using Fisher exact 
test. Incidence of HIV seroconversion during the study was cal-
culated by dividing the number of events by the total number 
of follow-up person-years, with 95% confidence intervals calcu-
lated using the exact Poisson confidence limits. A P value of <.05 
was considered statistically significant. Statistical analyses were 
performed in R (http://cran.r-project.org), version 3.3.2.
RESULTS
Study Flow
From 435 participants completing a screening visit, a total of 
398 individuals (395 MSM and 3 transgender women) met the 
study eligibility criteria and were randomized and completed 
a baseline visit. Two hundred participants were randomized to 
the iTAB arm and 198 were randomized to the SoC arm. Of 
37 screen failures (Figure 1), 8 subjects had newly diagnosed 
HIV (1.8% of all screened). Other reasons for screen failures 
included loss to follow-up prior to baseline (n = 10) and a with-
drawn consent (n = 9). At week 48, 324 (81.4%) participants 
were still on study.
Baseline Analysis
The mean age of participants was 35.2  years old (range, 
19–64 years; Table 1). Fifty percent were non-Hispanic white, 
28% were non-black Hispanic, and 15% identified as black alone 
or as part of multiple racial identity. Despite randomization, the 
iTAB arm as compared to the SoC arm (1) had lower education, 
HIV literacy, and likelihood of reporting income; (2) were less 
likely to have had an HIV-infected sexual partner for the past 4 
weeks or longer; (3) had higher levels of depressive symptoms 
(PHQ-9); and (4) had higher mean sexual compulsivity scores.
Study Follow-up
Seventy-four participants terminated study prior to week 48 (42 
[21%] in iTAB vs 32 [16.2%] in SoC; P = .25). The most common 
Figure 1. Consort diagram. Abbreviations: HIV, human immunodeficiency virus; LTFU, lost to follow up. 
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reasons for early termination were by participant request or per 
protocol discontinuation for missing 2 consecutive visits prior 
to week 48. Two serious adverse events occurred: pancreatitis, 
unrelated to study drug, and Fanconi syndrome, related to study 
drug. Two HIV seroconversions occurred over 577 person-years 
of follow-up with an incidence rate of 0.35 per 100 person-years 
(95% confidence interval [CI], .04–1.25 per 100 person-years). 
Both cases were in the iTAB arm (incidence rate, 0.7 per 100 per-
son-years [95% CI, .08–2.52]) compared to 0 (95% CI, 0–1.27) in 
the SoC arm (P = .25). Both of the HIV seroconverters reported 
discontinuing drug prior to seroconversion.
TFV-DP Adherence at Weeks 12 and 48
Overall adherence was high, with 320 of 361 (88.6%) subjects 
at week 12 and 264 of 320 (82.5%) of participants retained on 
study drug achieving TFV-DP ≥719 fmol/punch, whereas 171 
(47.4%) at week 12 and 141 (44.1%) at week 48 had TFV-DP 
≥1246 fmol/punch. Among participants with a DBS concentra-
tion at week 12, the iTAB arm had 166 (91.7%) who attained 
≥719 fmol/punch compared with 154 (85.6%) in the SoC arm 
(P =  .07; Figure 2). At week 48, 131 in the iTAB arm (83.4%) 
attained ≥719 fmol/punch compared with 133 (81.6%) in SoC 
(P = .77). For perfect adherence at week 12, the iTAB arm had 
92 (50.8%) who attained a DBS level ≥1246 fmol/punch com-
pared with 79 (43.9%) in SoC (P  =  .21). At week 48, partici-
pants in the iTAB arm showed better near-perfect adherence 
(≥1246 fmol/punch): 80 in the iTAB arm (51%) vs 61 (37.4%) 
in SoC arm (P = .02).
Primary TFV-DP Adherence Endpoint
For the primary analysis, we used a composite outcome of DBS 
TFV-DP ≥719  fmol/punch at week 12 visit and the last study 
visit through week 48 (eg, week 24, 36, or 48); no statistical 
difference was seen between the arms (144 [72.0%] in iTAB 
vs 137 [69.2%] in SoC; P = .58). In logistic regression (Table 2) 
adjusting for education, income, white race, non-English lan-
guage, and baseline depressive symptom score, the adjusted 
odds ratio for iTAB predicting the primary adherence outcome 
(≥719 fmol/punch) was 1.37 (95% CI, .87–2.17; P = .18).
In the secondary analysis used the composite outcome of 
DBS TFV-DP ≥1246  fmol/punch, there was a trend favoring 
iTAB compared to SoC (67 [33.5%] vs 49 [24.8%], respectively; 
P = .06). Of baseline factors, only age predicted adherence for 
the composite outcome at ≥1246 fmol/punch (older individu-
als were more adherent). After adjusting for age, the iTAB arm 
was more adherent for the composite adherence outcome using 
≥1246 fmol/punch (odds ratio [OR], 1.56 [95% CI, 1.00–2.42]) 
and age remained a significant predictor (OR, 1.03 [95% CI, 
1.01–10.6]).
FTC Adherence Analysis
At week 12, the iTAB arm had a higher proportion of subjects 
with plasma FTC concentrations greater than the 24-hour 
trough of >350 ng/mL, ie, dosing in past 24 hours, compared to 
those in the SoC arm (47.5% vs 33.3%; P = .007); this difference 
did not persist in week 24, 36, or 48 (all P > .05; see Figure 3). 
Mean plasma FTC concentrations were consistently higher in 
the iTAB arm, but this only was statistically significant at week 
12 (400.3 ng/mL vs 299.3 ng/mL; P = .009).
DISCUSSION
This randomized, controlled trial enrolled MSM and trans-
gender women compared a personalized daily text messaging 
(iTAB) system to SoC for adherence to TDF/FTC PrEP over 48 
Table 1. Baseline Characteristics
Characteristic
iTAB Arm
(n = 200)
Standard of Care
(n = 198) P Value
Gender
 Male 197 (98.5) 198 (100)
 Transgender women 3 (1.5) 0 (0) .25
Age, mean (SD) 35.1 (9.8) 35.4 (8.7) .44
Race .90
 Asian 7 (3.6) 5 (2.6)
 Black 26 (13.2) 26 (13.5)
 White 147 (74.6) 148 (76.7)
 Multiple 14 (7.1) 10 (5.2)
 Other 3 (1.5) 4 (2.1)
 Hispanic ethnicity 61 (30.8) 58 (29.4) .83
English primary language 188 (94.0) 192 (97) .23
Education
 Less than high school 4 (2.0) 0 (0) .05
 High school 20 (10.0) 11 (5.6)
 Some college 77 (38.5) 72 (36.4)
 Bachelor’ degree 64 (32.0) 68 (34.3)
 Some postgraduate 5 (2.5) 14 (7.1)
 Advanced degree 30 (15.0) 33 (16.7)
Household income
 <$2000/mo 43 (21.5) 42 (21.2) .02
 ≥$2000/mo 115 (57.5) 134 (67.7)
 Refuse 42 (21.0) 22 (11.1)
≥1 HIV+ partner for >4 wk 88 (44.0) 109 (55.1) .04
Condomless sex with ≥3 HIV+/ 
unknown partners past 3 mo
139 (70.2) 137 (69.2) >.99
Condomless sex with ≥1 partner 
and had STI in past 6 mo
31 (15.5) 35 (17.7) .59
Any STI at baseline 54 (27.0) 50 (25.3) .73
Any substance use (not marijuana) 
past 3 mo
152 (76.8) 136 (69.4) .11
DAST-10
 No or low 118 (59.6) 131 (66.9) .30
 Moderate 67 (33.9) 53 (27.0)
 Substantial 13 (6.6) 12 (6.1)
PHQ-9, mean (SD) 5.2 (4.9) 4.2 (4.4) .03
Sexual compulsivity score, mean 
(SD)
1.7 (0.5) 1.6 (0.5) .04
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: DAST-10, Drug Abuse Screening Test; HIV, human immunodeficiency virus; 
iTAB, individualized texting for adherence building; PHQ-9, Patient Health Questionnaire-9; 
SD, standard deviation; STI, sexually transmitted infection.
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weeks. Using a priori composite endpoints, the text messaging 
intervention did not significantly improve rates of minimally 
acceptable adherence (≥719 fmol/punch), our primary out-
come, but did improve near-perfect adherence (≥1246 fmol/
punch) a secondary outcome, through week 48. Specifically, 
for the near-perfect composite adherence endpoint using DBS 
TFV-DP data and adjusting for age, the OR was 1.56 (95% 
CI, 1.00–2.42) for the texting arm. For participants who com-
pleted week 48, 13.5% more participants crossed the threshold 
for near-perfect adherence in the iTAB arm compared to SoC. 
Finally, we observed significantly more with dosing in past 24 
hours by FTC concentrations among those assigned to the iTAB 
arm at week 12; however, this did not persist in later study visits.
Overall, the evidence supporting text messaging for improv-
ing PrEP adherence using biologic endpoints is somewhat 
mixed. The observed early (week 12) higher rates of adherence 
as per FTC concentrations suggest that text messaging may help 
to support routine dosing during PrEP initiation. Additionally, 
text messaging appears to help maintain near-perfect DBS 
levels of adherence over 48 weeks. We know that adherence 
tends to wane over time as was observed in this study across 
all study groups over 48 weeks. Despite this decrease over time, 
we hypothesize that the text messaging group who evidenced 
near-perfect adherence are likely to have formed strong daily 
habits that may lead to more sustainable adherence over the 
long term that will continue to stay above adequate thresholds 
even if adherence waned. Persons who are currently above an 
adequate threshold for adherence may subsequently fall below 
this threshold; therefore, maximizing adherence, even if above 
necessary levels seems proactively beneficial.
Given that protective levels of PrEP are associated with 
approximately 4 doses per week, there are some that suggest less 
than daily dosing could a viable strategy, but when considering 
the possibility of less than daily dosing, it is important to note 
that the most sustainable behaviors are those that are done daily 
Figure 2. Adherence by tenofovir diphosphate at week 12 and 48. Includes only subjects who complete study week. Numbers in cells represent percentage of subjects 
with a value greater than the stated cut point at the study week alone. *P < .05. Abbreviations: iTAB, individualized texting for adherence building; SoC, standard of care; 
Wk, study week.
Table  2. Multivariable Logistic Regression Comparing Primary 
Adherence Outcome (≥719 fmol/Punch) Between the Study Arms
Characteristic Adjusted OR (95% CI) P Value
iTAB arm 1.37 (.87–2.17) .18
College or greater education 2.10 (.99–4.45) .05
Monthly income of ≥$2000 0.91 (.50–1.65) .75
Income refused to answer 0.48 (.23–.99) .05
White race 1.72 (1.02–2.90) .04
Primary language other than English 0.41 (.15–1.12) .08
PHQ-9 score 0.96 (.92–1.02) .18
Multivariable logistic regression includes arm of study in intent-to-treat analysis for asso-
ciation with having >719 fmol/punch at week 12 and (if there was one) the last study visit 
up until week 48. Missing was considered nonadherent. Covariates were included in the 
model if they were associated with the outcome (P < .15) in univariate analysis. 
Abbreviations: CI, confidence interval; iTAB, individualized texting for adherence building; 
OR, odds ratio; PHQ-9, Patient Health Questionnaire-9.
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[31]. The HPTN 067 Adapt Study of on-demand PrEP found 
that, compared to daily dosing, participants who were using 
PrEP on demand were more likely to forget or not take a dose 
prior to possible exposures [32]. While iPERGAY was a success-
ful on-demand dosing schedule, participants had a high median 
number of doses per month (ie, 18 doses/month), suggesting 
routine PrEP use >4 days per week (ie, not entirely episodic) 
[33]. Furthermore, no study has shown noninferiority of epi-
sodic dosing to daily dosing for efficacy. The approved usage for 
TDF/FTC with daily dosing remains the most reliable means 
of HIV prevention, and text message prompts and motivators 
could be utilized to maintain optimal adherence.
Our study reached individuals at risk for HIV (HIV preva-
lence at screening was 1.8%) who were predominantly MSM 
who exhibited high retention and adherence over 48 weeks, 
which supports TDF/FTC as a durable, well-tolerated preven-
tion intervention. Our low HIV incidence rate was similar to 
that observed in another large-scale US PrEP demonstration 
project (ie, Demo Project, 0.4 per 100 person-years) [34]. There 
are several potential reasons for the high adherence and reten-
tion rates found in this demonstration project: (1) Many par-
ticipants in this cohort were enthusiastic PrEP early adopters 
who entered the study when insurance coverage was not widely 
available. As a result, participants may have used the study as 
the avenue to access PrEP; (2) CDC PrEP practice guidelines 
were delivered with experienced research staff that may have 
a stronger PrEP knowledge base than the general community, 
and (3) adherence in a research study is likely better than in the 
community as participants know adherence is being monitored. 
Additional real-world challenges such as managing prescription 
refills and insurance payments may decrease adherence, and it 
is unknown how effective text messaging would be in the con-
text of these structural barriers. Our study was not specifically 
examining predictors of PrEP adherence; however, as expected, 
demographic factors appeared to be particularly important 
including race, education, and income. The impact of these fac-
tors warrants continued study.
Other limitations include that, although our sample was 
relatively diverse, the diversity may not represent those who 
suffer disparities in HIV prevention or those who struggle 
with PrEP adherence. Our study did not include many indi-
viduals 18–24 years of age, whereas text message interven-
tions for adherence to HIV medications appear to have the 
strongest effect among populations where there is greater 
nonadherence (eg, youth) [15, 35]. Future text messaging in 
the context of PrEP may be best done among those persons 
who are at greatest risk for nonadherence and/or among 
more challenged subgroups (eg, young MSM, black MSM, 
women, transgender women).
In summary, adherence to PrEP in this study of mostly 
MSM was high with correspondingly low HIV incidence. 
Although the primary outcome was not significant for sus-
tained adequate adherence, iTAB daily texting improved 
overall durability of near-perfect adherence through 48 
weeks of follow-up. Individualized daily texting for adher-
ence is a low-burden ancillary tool that could be used to 
maximize long-term PrEP effectiveness by increasing 
near-perfect adherence. Future studies plan to examine the 
role of changing HIV risk over time on adherence and vari-
able trajectories of adherence, as well as predictors of inter-
vention engagement, including how specific messages may 
influence PrEP adherence.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility 
of the authors, so questions or comments should be addressed to the 
corresponding author.
Figure 3. Proportion with plasma emtricitabine concentration >24-hour trough (>350 ng/mL). *P < .05. Abbreviations: iTAB, individualized texting for adherence building; 
SoC, standard of care; Wk, study week.
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